Is sugammadex economically viable for routine use.

Area of Science:

• Anesthesiology
• Pharmacoeconomics
• Drug safety

Background:

• Sugammadex is a selective relaxant binding agent for reversing rocuronium or vecuronium.
• Its use is widespread globally, offering predictable reversal regardless of blockade depth.
• Sugammadex presents higher costs compared to traditional acetylcholine esterase inhibitors.

Purpose of the Study:

• To evaluate the cost-effectiveness of sugammadex based on current literature.
• To compare sugammadex reversal with traditional methods in terms of economic impact.
• To explore strategies for cost reduction, such as dose optimization.

Main Methods:

• Literature review of pharmacoeconomic studies on sugammadex reversal.
• Analysis of studies comparing sugammadex with cholinesterase inhibitors.
• Inclusion of studies examining specific clinical scenarios and cost-saving approaches.

Main Results:

• Limited evidence-based studies exist on the pharmacoeconomics of sugammadex.
• Studies indicate higher costs for sugammadex compared to cholinesterase inhibitors.
• One UK study analyzed the rocuronium/sugammadex concept versus succinylcholine in critical scenarios.

Conclusions:

• Sugammadex can reduce recovery times and potentially increase patient throughput.
• Cost-effectiveness is influenced by organizational factors and specific clinical contexts.
• Dose reduction strategies may contribute to cost savings.